ORCA Therapeutics Secures €2 Million in Financing to Advance Oncolytic Immunotherapy Development

Amsterdam, The Netherlands – 23 September 2024

ORCA Therapeutics B.V., a Dutch biopharmaceutical company pioneering innovative oncolytic immunotherapies for cancer treatment, today announced the successful completion of a €2 million financing round led by existing shareholders.

This strategic investment will accelerate the clinical development of the company’s lead product, ORCA-010, for early-stage prostate cancer.

“This funding is a pivotal milestone in our mission to transform cancer treatment through oncolytic immunotherapy,” said Dr. Wenliang Dong, CEO of ORCA Therapeutics. “The continued support from our investors validates the potential of our technology and will enable us to expedite the clinical development of ORCA-010, bringing new hope to cancer patients.”

About ORCA-010

ORCA-010 is a state-of-the-art oncolytic adenovirus therapy at the forefront of cancer treatment innovation. This potent immunotherapy is designed to achieve optimal tumor destruction while simultaneously fostering an immunostimulatory tumor microenvironment. The ongoing Phase I/IIA trial of ORCA-010 focuses on treatment-naïve, early-stage prostate cancer patients.

Interim clinical analyses have demonstrated:

  • ORCA-010’s promising efficacy
  • Consistent and long term activation of the tumor microenvironment
  • Induction of systemic anti-tumor immune responses

These compelling results position ORCA-010 for continued development in prostate cancer treatment and potentially other indications.

About ORCA Therapeutics BV

ORCA Therapeutics BV is a leader in immuno-oncology therapeutics, specializing in oncolytic viruses and innovative gene therapy approaches. The company is dedicated to translating cutting-edge scientific discoveries into effective therapeutic solutions, addressing unmet medical needs and improving patient outcomes globally.

For more information about our mission and ongoing projects, visit www.orca-therapeutics.com

Media Contact

Dr. Wenliang Dong, Ph.D., MBA
CEO, ORCA Therapeutics BV
Email: info@orca-therapeutics.com
Website: www.orca-therapeutics.com